Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Evaluation of the HemoCue WBC DIFF in leukopenic patient samples.

Kur DK, Agersnap N, Holländer NH, Pedersen OBV, Friis-Hansen L.

Int J Lab Hematol. 2020 Feb 10. doi: 10.1111/ijlh.13158. [Epub ahead of print]

PMID:
32039560
2.

Prognostic impact of Charlson's Age-Comorbidity Index and other risk factors in patients with pancreatic cancer.

Bagni K, Chen IM, Johansen AZ, Dehlendorff C, Jensen BV, Hansen CP, Preus Hasselby J, Holländer NH, Nissen M, Bjerregaard JK, Pfeiffer P, Yilmaz MK, Rasmussen LS, Nielsen SE, Johansen JS.

Eur J Cancer Care (Engl). 2020 Jan 6:e13219. doi: 10.1111/ecc.13219. [Epub ahead of print]

PMID:
31908093
3.

3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.

Iveson T, Boyd KA, Kerr RS, Robles-Zurita J, Saunders MP, Briggs AH, Cassidy J, Hollander NH, Tabernero J, Haydon A, Glimelius B, Harkin A, Allan K, McQueen J, Pearson S, Waterston A, Medley L, Wilson C, Ellis R, Essapen S, Dhadda AS, Harrison M, Falk S, Raouf S, Rees C, Olesen RK, Propper D, Bridgewater J, Azzabi A, Farrugia D, Webb A, Cunningham D, Hickish T, Weaver A, Gollins S, Wasan H, Paul J.

Health Technol Assess. 2019 Dec;23(64):1-88. doi: 10.3310/hta23640.

4.

Radiotherapy for metastatic spinal cord compression with increased radiation doses (RAMSES-01): a prospective multicenter study.

Rades D, Hansen O, Jensen LH, Dziggel L, Staackmann C, Doemer C, Cacicedo J, Conde-Moreno AJ, Segedin B, Ciervide-Jurio R, Rubio-Rodriguez C, Perez-Romasanta LA, Alvarez-Gracia A, Dennis K, Ferrer-Albiach C, Navarro-Martin A, Lopez-Campos F, Jankarashvili N, Janssen S, Olbrich D, Holländer NH.

BMC Cancer. 2019 Nov 29;19(1):1163. doi: 10.1186/s12885-019-6390-x.

5.

Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer.

Chen IM, Johansen AZ, Dehlendorff C, Jensen BV, Bojesen SE, Pfeiffer P, Bjerregaard JK, Nielsen SE, Andersen F, Holländer NH, Yilmaz MK, Rasmussen LS, Johansen JS.

Cancer Epidemiol Biomarkers Prev. 2020 Jan;29(1):176-184. doi: 10.1158/1055-9965.EPI-19-0672. Epub 2019 Nov 4.

PMID:
31685562
6.

Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer.

Chen IM, Willumsen N, Dehlendorff C, Johansen AZ, Jensen BV, Hansen CP, Hasselby JP, Bojesen SE, Pfeiffer P, Nielsen SE, Holländer NH, Yilmaz MK, Karsdal M, Johansen JS.

Int J Cancer. 2019 Oct 23. doi: 10.1002/ijc.32751. [Epub ahead of print]

PMID:
31642523
7.

MyHealth: specialist nurse-led follow-up in breast cancer. A randomized controlled trial - development and feasibility.

Saltbæk L, Karlsen RV, Bidstrup PE, Høeg BL, Zoffmann V, Horsbøl TA, Holländer NH, Svendsen MN, Christensen HG, Dalton SO, Johansen C.

Acta Oncol. 2019 May;58(5):619-626. doi: 10.1080/0284186X.2018.1563717. Epub 2019 Jan 30.

PMID:
30698065
8.

Palliative radiotherapy to dominant symptomatic lesion in patients with hormone refractory prostate cancer (PRADO).

Carl J, Rades D, Doemer C, Setter C, Dunst J, Holländer NH.

Radiat Oncol. 2019 Jan 10;14(1):3. doi: 10.1186/s13014-019-1209-0.

9.

Outcomes After Radiotherapy Alone for Metastatic Spinal Cord Compression in Patients with Oligo-metastatic Breast Cancer.

Rades D, Panzner A, Janssen S, Dunst J, Veninga T, Holländer NH, Schild SE.

Anticancer Res. 2018 Dec;38(12):6897-6903. doi: 10.21873/anticanres.13066.

PMID:
30504407
10.

A Matched-Pair Study Comparing Surgery Plus Neoadjuvant Radio-Chemotherapy and Surgery Alone for High Rectal Cancers.

Rades D, Vogelsang RP, Treder M, Janssen S, Schild SE, Holländer NH, Gögenur I.

Anticancer Res. 2018 Dec;38(12):6877-6880. doi: 10.21873/anticanres.13063.

PMID:
30504404
11.

SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer.

Robles-Zurita J, Boyd KA, Briggs AH, Iveson T, Kerr RS, Saunders MP, Cassidy J, Hollander NH, Tabernero J, Segelov E, Glimelius B, Harkin A, Allan K, McQueen J, Pearson S, Waterston A, Medley L, Wilson C, Ellis R, Essapen S, Dhadda AS, Hughes R, Falk S, Raouf S, Rees C, Olesen RK, Propper D, Bridgewater J, Azzabi A, Farrugia D, Webb A, Cunningham D, Hickish T, Weaver A, Gollins S, Wasan HS, Paul J.

Br J Cancer. 2018 Nov;119(11):1332-1338. doi: 10.1038/s41416-018-0319-z. Epub 2018 Nov 13.

12.

Potential Prognostic Factors of Downstaging Following Preoperative Chemoradiation for High Rectal Cancer.

Treder M, Vogelsang RP, Janssen S, Schild SE, Holländer NH, Rades D.

In Vivo. 2018 Nov-Dec;32(6):1481-1484. doi: 10.21873/invivo.11403.

13.

Role of Neoadjuvant Radio-chemotherapy for the Treatment of High Rectal Cancer.

Treder M, Janssen S, Holländer NH, Schild SE, Rades D.

Anticancer Res. 2018 Sep;38(9):5371-5377. doi: 10.21873/anticanres.12866.

PMID:
30194191
14.

Preliminary Results from a Prospective Study Comparing White Blood Cell and Neutrophil Counts from a Laboratory to Those Measured with a New Device in Patients with Breast Cancer.

Lohman AC, VAN Rijn I, Lindhardt CL, Vonthein R, Rades D, Holländer NH.

In Vivo. 2018 Sep-Oct;32(5):1283-1288. doi: 10.21873/invivo.11378.

15.

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.

Iveson TJ, Kerr RS, Saunders MP, Cassidy J, Hollander NH, Tabernero J, Haydon A, Glimelius B, Harkin A, Allan K, McQueen J, Scudder C, Boyd KA, Briggs A, Waterston A, Medley L, Wilson C, Ellis R, Essapen S, Dhadda AS, Harrison M, Falk S, Raouf S, Rees C, Olesen RK, Propper D, Bridgewater J, Azzabi A, Farrugia D, Webb A, Cunningham D, Hickish T, Weaver A, Gollins S, Wasan HS, Paul J.

Lancet Oncol. 2018 Apr;19(4):562-578. doi: 10.1016/S1470-2045(18)30093-7.

16.

High-precision radiotherapy of motor deficits due to metastatic spinal cord compression (PRE-MODE): a multicenter phase 2 study.

Rades D, Cacicedo J, Conde-Moreno AJ, Doemer C, Dunst J, Lomidze D, Segedin B, Olbrich D, Holländer NH.

BMC Cancer. 2017 Dec 4;17(1):818. doi: 10.1186/s12885-017-3844-x.

17.

Incidence of pancreatic cancer in Denmark: 70 years of registration, 1943-2012.

Weble TC, Bjerregaard JK, Kissmeyer P, Vyberg M, Hansen CP, Holländer NH, Johansen C.

Acta Oncol. 2017 Dec;56(12):1763-1768. doi: 10.1080/0284186X.2017.1351036. Epub 2017 Jul 25.

PMID:
28741399
18.

The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer.

Johansen JS, Calatayud D, Albieri V, Schultz NA, Dehlendorff C, Werner J, Jensen BV, Pfeiffer P, Bojesen SE, Giese N, Nielsen KR, Nielsen SE, Yilmaz M, Holländer NH, Andersen KK.

Int J Cancer. 2016 Nov 15;139(10):2312-24. doi: 10.1002/ijc.30291. Epub 2016 Aug 16.

19.

Less pitfalls and variation in population based cancer survival comparisons within the European Union: Lessons from colorectal cancer patients in neighbouring regions in Denmark and Germany - The Fehmarn Belt project.

Storm HH, Engholm G, Pritzkuleit R, Kejs AM, Katalinic A, Dunst J, Holländer NH.

Eur J Cancer. 2015 Jun;51(9):1188-98. doi: 10.1016/j.ejca.2014.11.006. Epub 2014 Dec 4.

PMID:
25483784
20.

Tissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line Capecitabine and Oxaliplatin with or without Bevacizumab.

Boisen MK, Dehlendorff C, Linnemann D, Nielsen BS, Larsen JS, Osterlind K, Nielsen SE, Tarpgaard LS, Qvortrup C, Pfeiffer P, Holländer NH, Keldsen N, Hansen TF, Jensen BB, Høgdall EV, Jensen BV, Johansen JS.

PLoS One. 2014 Oct 15;9(10):e109430. doi: 10.1371/journal.pone.0109430. eCollection 2014.

21.

Positron emission tomography/computed tomography and biomarkers for early treatment response evaluation in metastatic colon cancer.

Engelmann BE, Loft A, Kjær A, Nielsen HJ, Gerds TA, Benzon EV, Brünner N, Christensen IJ, Hansson SH, Holländer NH, Kristensen MH, Löfgren J, Markova E, Sloth C, Højgaard L.

Oncologist. 2014 Feb;19(2):164-72. doi: 10.1634/theoncologist.2013-0229. Epub 2014 Jan 22.

22.

MicroRNA biomarkers in whole blood for detection of pancreatic cancer.

Schultz NA, Dehlendorff C, Jensen BV, Bjerregaard JK, Nielsen KR, Bojesen SE, Calatayud D, Nielsen SE, Yilmaz M, Holländer NH, Andersen KK, Johansen JS.

JAMA. 2014 Jan 22-29;311(4):392-404. doi: 10.1001/jama.2013.284664.

PMID:
24449318
23.

Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.

Boisen MK, Johansen JS, Dehlendorff C, Larsen JS, Osterlind K, Hansen J, Nielsen SE, Pfeiffer P, Tarpgaard LS, Holländer NH, Keldsen N, Hansen TF, Jensen BB, Jensen BV.

Ann Oncol. 2013 Oct;24(10):2554-9. doi: 10.1093/annonc/mdt253. Epub 2013 Jul 17.

24.

Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer.

Schultz NA, Christensen IJ, Werner J, Giese N, Jensen BV, Larsen O, Bjerregaard JK, Pfeiffer P, Calatayud D, Nielsen SE, Yilmaz MK, Holländer NH, Wøjdemann M, Bojesen SE, Nielsen KR, Johansen JS.

PLoS One. 2013 Jun 26;8(6):e67059. doi: 10.1371/journal.pone.0067059. Print 2013.

25.

Prognostic implications of ventricular ectopy one week, one month, and sixteen months after an acute myocardial infarction. Danish Study Group on Verapamil in Myocardial Infarction.

Vaage-Nilsen M, Rasmussen V, Hansen JF, Hagerup L, Sørensen MB, Pedersen-Bjergaard O, Mellemgaard K, Holländer NH, Nielsen I, Sigurd BM.

Clin Cardiol. 1998 Dec;21(12):905-11.

26.

Effect of verapamil on arrhythmias and heart rate during 16 months following an acute myocardial infarction. The Danish Study Group on Verapamil in Myocardial Infarction.

Vaage-Nilsen M, Rasmussen V, Hansen JF, Hagerup L, Sørensen MB, Pedersen-Bjergaard O, Mellemgaard K, Holländer NH, Nielsen I, Sigurd BM.

Cardiovasc Drugs Ther. 1994 Feb;8(1):147-51.

PMID:
8086325
27.

[The circulating occupational medical record in the county of Roskilde].

Brendstrup T, Holländer NH, Christensen O, Gregersen P, Jensen F.

Ugeskr Laeger. 1993 Oct 11;155(41):3294-8. Danish.

PMID:
8256324
28.

Ceftriaxone versus latamoxef in febrile neutropenic patients: empirical monotherapy in patients with solid tumours.

Oturai PS, Holländer NH, Hansen OP, Boas J, Bruun BG, Frimodt-Møller N, Dombernowsky P, Hansen HH.

Eur J Cancer. 1993;29A(9):1274-9.

PMID:
8343267
30.

Effect of verapamil on ischemia and ventricular arrhythmias after an acute myocardial infarction: prognostic implications. The Danish Verapamil Infarction Trial II Study Group.

Vaage-Nilsen M, Rasmussen V, Hansen JF, Hagerup L, Sørensen MB, Bjergaard OP, Mellemgaard K, Holländer NH, Nielsen I, Sigurd B.

J Cardiovasc Pharmacol. 1991;18 Suppl 6:S26-9.

PMID:
1725913
31.

Nuclear fluorescing particles (F-bodies) in lymphocytes in chronic lymphocytic leukaemia.

Lisse IM, Holländer NH, Thomsen JL.

Scand J Haematol. 1983 Apr;30(4):374-8.

PMID:
6304865
32.

Fluorescing particles (F-bodies) in lymphocytes in chronic lymphocytic leukaemia resembling Y-bodies.

Lisse IM, Thomsen JL, Holländer NH.

Scand J Haematol. 1980 Jul;25(1):93-5.

PMID:
6255554
33.

[Circulating amylase complexes. Diagnosis and clinical features in 4 cases of macroamylasemia].

Holländer NH, Magid E.

Ugeskr Laeger. 1980 Jan 14;142(3):153-5. Danish. No abstract available.

PMID:
6153479

Supplemental Content

Loading ...
Support Center